Literature DB >> 6245831

Cefotaxime kinetics after intravenous and intramuscular injection of single and multiple doses.

H C Neu, P Aswapokee, K P Fu, I Ho, C Matthijssen.   

Abstract

The kinetics of cefotaxime, a cephalosporin with an unusually broad antibacterial spectrum, were examined in humans after intravenous bolus injection, intravenous infusion every 6 hr for 14 days, and intramuscular injection every 8 hr for 10 days. Mean peak serum level after bolus injection of 500 mg was 37.9 microgram/ml; after 1 gm, 102.4 microgram/ml; and after 2 gm, 214.1 microgram/ml. The half-life (t1/2) was 1 hr for the 3 doses. Total serum clearance was the same for all doses. Overall excretion was 50% to 60%; part of the drug was excreted as the desacetyl derivative. After multiple intravenous infusion the elimination rate constants and t1/2 were the same on days 1 and 15. Assayable levels were present on all days 5 min before injection of a dose. Multiple intramuscular injections of 500 mg produced serum levels of 9.2 to 11.9 microgram/ml. The t1/2 was 0.93 hr. Mean serum levels at 8 hr ranged from 0.08 to 0.55 microgram/ml. Serum levels produced by intravenous infusion or intramuscular injection were inhibitory for most (90%) aerobic gram-positive and gram-negative organisms susceptible to cefotaxime.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6245831     DOI: 10.1038/clpt.1980.96

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

1.  The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination.

Authors:  R M Ings; D S Reeves; L O White; R P Bax; M J Bywater; H A Holt
Journal:  J Pharmacokinet Biopharm       Date:  1985-04

2.  The pharmacokinetics of new cephalosporins: significance in clinical practice.

Authors:  H C Neu
Journal:  Bull N Y Acad Med       Date:  1984-05

3.  Clinical evaluation of cefotaxime for therapy of lower respiratory tract infections.

Authors:  C J Schleupner; J C Engle
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

4.  Serum bactericidal activity of moxalactam and cefotaxime with and without tobramycin against Pseudomonas aeruginosa and Staphylococcus aureus.

Authors:  H Lagast; S H Zinner; J Klastersky
Journal:  Antimicrob Agents Chemother       Date:  1981-10       Impact factor: 5.191

5.  Pharmacokinetics of ceftriaxone in humans.

Authors:  I H Patel; S Chen; M Parsonnet; M R Hackman; M A Brooks; J Konikoff; S A Kaplan
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

6.  Microbiological efficacy and pharmacokinetics of prophylactic antibiotics in liver transplant patients.

Authors:  P M Arnow; K Furmaga; J P Flaherty; D George
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

Review 7.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

8.  Cefotaxime diffusion into cerebrospinal fluid of children with meningitis.

Authors:  B I Asmar; M C Thirumoorthi; J A Buckley; D M Kobos; A S Dajani
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

Review 9.  Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-03       Impact factor: 9.546

Review 10.  Cefoperazone: A review of its in vitro antimicrobial activity, pharmacological properties and therapeutic efficacy.

Authors:  R N Brogden; A Carmine; R C Heel; P A Morley; T M Speight; G S Avery
Journal:  Drugs       Date:  1981-12       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.